ciprofibrate has been researched along with thromboxane b2 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, CK; Glauert, HP; Lay, LT; Robertson, LW; Tai, HH; Wilson, MW | 1 |
| Glauert, HP; Leung, LK | 1 |
| Glauert, HP; Hong, JT; Leung, LK; Wilson, MW | 1 |
| Cibulova, L; Fedelesova, V; Gajdos, M; Huttova, D; Krivosikova, Z; Mongiellova, V; Polak, F | 1 |
4 other study(ies) available for ciprofibrate and thromboxane b2
| Article | Year |
|---|---|
Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.
Topics: Acyl-CoA Oxidase; Animals; Clofibric Acid; Decanoic Acids; Dinoprost; Dinoprostone; Eicosanoids; Fibric Acids; Fluorocarbons; Gene Expression Regulation, Enzymologic; Hypolipidemic Agents; Immunoassay; Leukotriene C4; Liver; Male; Microbodies; Oxidoreductases; Rats; Rats, Sprague-Dawley; Thromboxane B2 | 1995 |
Reduction of the concentrations of prostaglandins E2 and F2alpha, and thromboxane B2 in cultured rat hepatocytes treated with the peroxisome proliferator ciprofibrate.
Topics: Acyl-CoA Oxidase; Analysis of Variance; Animals; Cell Division; Cells, Cultured; Clofibric Acid; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Fibric Acids; Gene Expression Regulation, Neoplastic; Hypolipidemic Agents; Liver; Male; Microbodies; Oxidoreductases; Rats; Rats, Sprague-Dawley; Thromboxane B2 | 1996 |
Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on eicosanoid concentrations in rat liver.
Topics: Animals; Cells, Cultured; Clofibric Acid; Decanoic Acids; Dinoprost; Dinoprostone; Eicosanoids; Fibric Acids; Fluorocarbons; Hypolipidemic Agents; Kinetics; Liver; Microbodies; Rats; Thromboxane B2; Time Factors | 1997 |
[The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Platelet Aggregation Inhibitors; Thromboxane B2 | 1999 |